Weekly Research Analysts’ Ratings Updates for Eton Pharmaceuticals (ETON)

A number of research firms have changed their ratings and price targets for Eton Pharmaceuticals (NASDAQ: ETON):

• 8/14/2026 – Eton Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $60.00 to $68.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Eton Pharmaceuticals had its “buy” rating reaffirmed by B. Riley Financial, Inc.. They now have a $70.00 price target on the stock, up from $40.00.
• 8/14/2026 – Eton Pharmaceuticals had its price target raised by HC Wainwright from $65.00 to $70.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Eton Pharmaceuticals had its price target raised by HC Wainwright from $57.00 to $65.00. They now have a “buy” rating on the stock.
• 7/28/2026 – Eton Pharmaceuticals had its price target raised by Craig Hallum from $40.00 to $62.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Eton Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Eton Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $60.00 price target on the stock.
• 7/16/2026 – Eton Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 7/13/2026 – Eton Pharmaceuticals was downgraded by Zacks Research from “hold” to “strong sell”.

Insiders Place Their Bets

In other news, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Krempa sold 19,679 shares of the company’s stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the sale, the insider directly owned 25,249 shares of the company’s stock, valued at $794,586.03. The trade was a 43.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by company insiders.

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.